BTLA and asthma: We demonstrated that inducing HVEM-BTLA inhibitory signaling attenuated airway inflammation, reduced goblet cell hyperplasia, and reduced AHR in vivo and attenuated Th17 immune response ex vivo, therefore, supporting its therapeutic potential in treating steroid-resistant asthma.